RIGHTWARE
4.1.2022 08:02:14 CET | Business Wire | Press release
Rightware today released Kanzi One, concluding a highly successful and oversubscribed beta program announced in September. The first automotive HMI toolchain to be fully compatible with Android™, Kanzi One delivers industry-leading 3D graphics and a new UI workflow, empowering automakers to create compelling new user experiences with visual excellence and maximum productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005425/en/
“As announced at IAA in Munich, Kanzi One is a game-changer for creativity and productivity by automakers,” said Rightware CEO Freddie Geier. “We are grateful for the positive feedback from customers and partners since our product launch, and we eagerly await the new Signature UIs they create with Kanzi One.”
Rightware’s goal with Kanzi One is to inspire OEMs and Tier 1 suppliers with impressive rendering capabilities and a powerful 3D graphics engine, the deepest Android integration for next generation infotainment systems, and a straightforward workflow that unleashes HMI possibilities.
Kanzi One lets manufacturers deliver future-looking user experiences for advanced HMIs in less than half the time with teams half the size and with significantly less coding compared with traditional methods.
All-in-One Solution
In addition to the core Kanzi framework consisting of Kanzi Studio and Kanzi Engine, Kanzi One delivers further value to automakers by including a growing list of feature packs.
Initially, five feature packs are included: Kanzi Connect makes it easy to share data, content, and services across screens and devices; Kanzi Maps enhances navigation with creative visualization; Kanzi Particles enables astounding visual effects and animations; Kanzi Autostereoscopy enables realistic depth effects; and the new Kanzi VR makes it easy to validate designs in an early phase by placing live UIs inside a virtual car interior and interacting with the screens with or without a virtual reality headset.
“We are certain that Kanzi One will transform the in-car user interfaces of today into tomorrow’s Signature UIs—highly appealing, easy-to-use, and true to their brand,” said Geier. “We invite all friends and observers of innovation in the automotive industry to explore the possibilities of Kanzi One, and count on us to drive HMI development to the next level.”
Due to the rapidly rising health risks associated with covid, Rightware made the decision not to attend CES 2022. Instead, the company will kick off a customer road show to present Kanzi One as conditions permit. To request a virtual or in-person meeting and to read descriptions of the latest Kanzi One demonstrations, please visit www.rightware.com/kanzi-one-at-ces-2022 or contact sales@rightware.com .
About Rightware
Rightware is the company behind the Kanzi family of tools and services for design and development of advanced digital user interfaces. Our mission is to help automakers increase brand value with highly customized signature user interfaces. As a ThunderSoft company, our combined skills and assets allow us to deliver fully integrated HMI solutions, engineering support, and design services. Rightware is headquartered in Finland and has a presence in China, Germany, Italy, Japan, South Korea, UK, and USA. Kanzi is the market-leading automotive UI tool trusted by over 50 automotive brands across the globe. www.rightware.com
Android is a trademark of Google LLC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005425/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom